Becton Dickinson’s stock bounces as FDA addresses supply issue with blood-culture vials

Shares of Becton Dickinson & Co. bounced back Wednesday toward their first gain in seven sessions after the Food and Drug Administration addressed supply issues surrounding blood-culture vials.

Previous post While Carvana’s stock is soaring, bondholders see a good time to exit
Next post Republicans say that limiting immigration will help reduce inflation. Economists aren’t so sure.